{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:56:24Z","timestamp":1792443384274,"version":"4.5.0"},"reference-count":269,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04763-8","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:34:17Z","timestamp":1783089257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted nanomedicine strategies for Alzheimer\u2019s disease therapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Mustafa T.","family":"Ardah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baraa Mohammed","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashree","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Thyagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Shankhyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasulbek","family":"Eshmetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6517-8163","authenticated-orcid":false,"given":"Zokir","family":"Ataullaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4763_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114139","volume":"244","author":"X Bi","year":"2024","unstructured":"Bi X, Cao N, He J. Recent advances in nanoenzymes for Alzheimer\u2019s disease treatment. Colloids Surf, B. 2024;244:114139.","journal-title":"Colloids Surf, B"},{"issue":"4","key":"4763_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/dvdy.762","volume":"254","author":"J Cai","year":"2025","unstructured":"Cai J, Liu Y, Fan H. Review on pathogenesis and treatment of Alzheimer\u2019s disease. Dev Dyn. 2025;254(4):296\u2013309.","journal-title":"Dev Dyn"},{"key":"4763_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clinbiochem.2019.08.005","volume":"73","author":"R Matej","year":"2019","unstructured":"Matej R, Tesar A, Rusina R. Alzheimer\u2019s disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview. Clin Biochem. 2019;73:26\u201331.","journal-title":"Clin Biochem"},{"issue":"10","key":"4763_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3390\/antiox13101208","volume":"13","author":"H Fanlo-Ucar","year":"2024","unstructured":"Fanlo-Ucar H, Pic\u00f3n-Pag\u00e8s P, Herrera-Fern\u00e1ndez V, Ill-Raga G, Mu\u00f1oz FJ. The dual role of amyloid Beta-Peptide in oxidative stress and inflammation: unveiling their connections in Alzheimer\u2019s disease etiopathology. Antioxidants. 2024;13(10):1208.","journal-title":"Antioxidants"},{"issue":"11","key":"4763_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/clinchem\/hvad139","volume":"69","author":"JH Kang","year":"2023","unstructured":"Kang JH, Korecka M, Lee EB, Cousins KA, Tropea TF, Chen-Plotkin AA, et al. Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology. Clin Chem. 2023;69(11):1247\u201359.","journal-title":"Clin Chem"},{"issue":"1","key":"4763_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248.","journal-title":"Signal Transduct Target Ther"},{"key":"4763_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.742408","volume":"14","author":"MB Abubakar","year":"2022","unstructured":"Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, et al. Alzheimer\u2019s disease: an update and insights into pathophysiology. Front Aging Neurosci. 2022;14:742408.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"4763_CR8","doi-asserted-by":"publisher","first-page":"2471677","DOI":"10.1080\/27694127.2025.2471677","volume":"4","author":"G Angst","year":"2025","unstructured":"Angst G, Jia N, Esqueda LET, Fan Y, Cai Q, Wang C. Autophagy in alzheimer disease pathogenesis and its therapeutic values. Autophagy Reports. 2025;4(1):2471677.","journal-title":"Autophagy Reports"},{"issue":"17","key":"4763_CR9","doi-asserted-by":"publisher","first-page":"9690","DOI":"10.3390\/ijms25179690","volume":"25","author":"A Dey","year":"2024","unstructured":"Dey A, Ghosh S, Rajendran RL, Bhuniya T, Das P, Bhattacharjee B, et al. Alzheimer\u2019s disease pathology and assistive nanotheranostic approaches for its therapeutic interventions. Int J Mol Sci. 2024;25(17):9690.","journal-title":"Int J Mol Sci"},{"key":"4763_CR10","doi-asserted-by":"publisher","unstructured":"Sonawane SK, Dubey T, Balmik AA, Das R, and Chinnathambi S. in Alzheimer's Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities, ed. T. Govindaraju, R. Soc. Chem. 2022; ch. 3, pp. 58\u201388. https:\/\/doi.org\/10.1039\/9781839162732-00058","DOI":"10.1039\/9781839162732-00058"},{"key":"4763_CR11","doi-asserted-by":"publisher","DOI":"10.18071\/isz.74.0379","author":"N Balazs","year":"2021","unstructured":"Balazs N, Bereczki D, Kov\u00e1cs T. Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias. Ideggyogy Sz. 2021. https:\/\/doi.org\/10.18071\/isz.74.0379.","journal-title":"Ideggyogy Sz"},{"issue":"1","key":"4763_CR12","first-page":"8501693","volume":"2016","author":"J Folch","year":"2016","unstructured":"Folch J, Petrov D, Ettcheto M, Abad S, S\u00e1nchez-L\u00f3pez E, Garc\u00eda ML, et al. Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast. 2016;2016(1):8501693.","journal-title":"Neural Plast"},{"issue":"5","key":"4763_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2174\/1389450122666211118125233","volume":"23","author":"M Kumar","year":"2022","unstructured":"Kumar M, Bansal N. A revisit to etiopathogenesis and therapeutic strategies in Alzheimer\u2019s disease. Curr Drug Targets. 2022;23(5):486\u2013512.","journal-title":"Curr Drug Targets"},{"key":"4763_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3897\/pharmacia.70.e99311","volume":"70","author":"HA Al-hussaniy","year":"2023","unstructured":"Al-hussaniy HA, Alkhafaje Z, Altamimi ZS, Oraibi AI, Abdalhassan AH, Abdulhamza HM, et al. Memantine and its role in parkinsonism, seizure, depression, migraine headache, and Alzheimer\u2019s disease. Pharmacia. 2023;70:291\u20137.","journal-title":"Pharmacia"},{"issue":"7","key":"4763_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40266-016-0372-3","volume":"33","author":"CW Wong","year":"2016","unstructured":"Wong CW. Pharmacotherapy for dementia: a practical approach to the use of cholinesterase inhibitors and memantine. Drugs Aging. 2016;33(7):451\u201360.","journal-title":"Drugs Aging"},{"key":"4763_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/2347-8659.167305","volume":"2","author":"S-M Li","year":"2015","unstructured":"Li S-M, Mo M-S, Xu P-Y. Progress in mechanisms of acetylcholinesterase inhibitors and memantine for treatment of Alzheimer\u2019s disease. Neuroimmunol Neuroinflammat. 2015;2:274\u201380.","journal-title":"Neuroimmunol Neuroinflammat"},{"issue":"1","key":"4763_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/neup.12626","volume":"40","author":"R Sengoku","year":"2020","unstructured":"Sengoku R. Aging and Alzheimer\u2019s disease pathology. Neuropathology. 2020;40(1):22\u20139.","journal-title":"Neuropathology"},{"issue":"6","key":"4763_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.2174\/1566524022666220404112843","volume":"23","author":"S Bagga","year":"2023","unstructured":"Bagga S, Kumar M. Current status of Alzheimer\u2019s disease and pathological mechanisms investigating the therapeutic molecular targets. Curr Mol Med. 2023;23(6):492\u2013508.","journal-title":"Curr Mol Med"},{"issue":"2","key":"4763_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/nnm-2022-0108","volume":"18","author":"FS Alhodieb","year":"2023","unstructured":"Alhodieb FS, Rahman MA, Barkat MA, Alanezi AA, Barkat HA, Hadi HA, et al. Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer\u2019s disease. Nanomedicine. 2023;18(2):145\u201368.","journal-title":"Nanomedicine"},{"key":"4763_CR20","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s549893","author":"L Gao","year":"2025","unstructured":"Gao L, Wang J, Bi Y. Nanotechnology for neurodegenerative diseases: recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics. Int J Nanomedicine. 2025. https:\/\/doi.org\/10.2147\/ijn.s549893.","journal-title":"Int J Nanomedicine"},{"key":"4763_CR21","first-page":"151","volume-title":"Nanotechnology-Based Formulations for Drug Targeting to the Central Nervous System","author":"J Jamp\u00edlek","year":"2019","unstructured":"Jamp\u00edlek J, Kr\u00e1lov\u00e1 K. Nanotechnology-Based Formulations for Drug Targeting to the Central Nervous System. Nanoparticulate drug delivery systems: Apple Academic Press; 2019. p. 151\u2013220."},{"key":"4763_CR22","doi-asserted-by":"publisher","first-page":"1630475","DOI":"10.3389\/fphar.2025.1630475","volume":"16","author":"N Chengebroyen","year":"2025","unstructured":"Chengebroyen N, Seelan A, Thajudeen KY, Alshehri S, Biswas A, Adur I, et al. Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments-a state-of-the-art update. Front Pharmacol. 2025;16:1630475.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4763_CR23","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s12035-022-03164-z","volume":"60","author":"P Kaur","year":"2023","unstructured":"Kaur P, Khera A, Alajangi HK, Sharma A, Jaiswal PK, Singh G, et al. Role of tau in various tauopathies, treatment approaches, and emerging role of nanotechnology in neurodegenerative disorders. Mol Neurobiol. 2023;60(3):1690\u2013720.","journal-title":"Mol Neurobiol"},{"issue":"12","key":"4763_CR24","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2174\/1389450122999210104205018","volume":"22","author":"I Kaur","year":"2021","unstructured":"Kaur I, Kumar A, Behl T, Setia D. Recent advances in nanotechnology-based drug delivery approaches for Alzheimer disease. Curr Drug Targets. 2021;22(12):1404\u201323.","journal-title":"Curr Drug Targets"},{"issue":"42","key":"4763_CR25","doi-asserted-by":"publisher","first-page":"28502","DOI":"10.1021\/acsnano.4c09800","volume":"18","author":"M Wu","year":"2024","unstructured":"Wu M, Zhao Y, Zhang C, Pu K. Advancing proteolysis targeting chimera (PROTAC) nanotechnology in protein homeostasis reprograming for disease treatment. ACS Nano. 2024;18(42):28502\u201330.","journal-title":"ACS Nano"},{"issue":"7","key":"4763_CR26","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3390\/pharmaceutics15072011","volume":"15","author":"M Abudurexiti","year":"2023","unstructured":"Abudurexiti M, Zhao Y, Wang X, Han L, Liu T, Wang C, et al. Bio-inspired nanocarriers derived from stem cells and their extracellular vesicles for targeted drug delivery. Pharmaceutics. 2023;15(7):2011.","journal-title":"Pharmaceutics"},{"key":"4763_CR27","doi-asserted-by":"publisher","unstructured":"Anwarkhan S, Koilpillai J, Narayanasamy D. Utilizing multifaceted approaches to target drug delivery in the brain: from nanoparticles to biological therapies. Cureus. 2024;16(9). https:\/\/doi.org\/10.7759\/cureus.68419","DOI":"10.7759\/cureus.68419"},{"issue":"12","key":"4763_CR28","doi-asserted-by":"publisher","first-page":"2304180","DOI":"10.1002\/adhm.202304180","volume":"13","author":"M Battaglini","year":"2024","unstructured":"Battaglini M, Marino A, Montorsi M, Carmignani A, Ceccarelli MC, Ciofani G. Nanomaterials as microglia modulators in the treatment of central nervous system disorders. Adv Healthcare Mater. 2024;13(12):2304180.","journal-title":"Adv Healthcare Mater"},{"issue":"3","key":"4763_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/brx2.27","volume":"1","author":"G Cheng","year":"2023","unstructured":"Cheng G, Xie A, Yan Z, Zhu X, Song Y, Chen T. Nanomedicines for Alzheimer\u2019s disease: therapies based on pathological mechanisms. Brain-X. 2023;1(3):e27.","journal-title":"Brain-X"},{"key":"4763_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.989471","volume":"10","author":"MM Rhaman","year":"2022","unstructured":"Rhaman MM, Islam MR, Akash S, Mim M, Noor Alam M, Nepovimova E, et al. Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance. Front Cell Develop Biol. 2022;10:989471.","journal-title":"Front Cell Develop Biol"},{"issue":"1","key":"4763_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","volume":"25","author":"X Li","year":"2017","unstructured":"Li X, Tsibouklis J, Weng T, Zhang B, Yin G, Feng G, et al. Nano carriers for drug transport across the blood\u2013brain barrier. J Drug Target. 2017;25(1):17\u201328.","journal-title":"J Drug Target"},{"issue":"45","key":"4763_CR32","doi-asserted-by":"publisher","first-page":"2203678","DOI":"10.1002\/smll.202203678","volume":"18","author":"L Wang","year":"2022","unstructured":"Wang L, Shi Y, Jiang J, Li C, Zhang H, Zhang X, et al. Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy. Small. 2022;18(45):2203678.","journal-title":"Small"},{"issue":"4","key":"4763_CR33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10072-024-07871-4","volume":"46","author":"N Dong","year":"2025","unstructured":"Dong N, Ali-Khiavi P, Ghavamikia N, Pakmehr S, Sotoudegan F, Hjazi A, et al. Nanomedicine in the treatment of Alzheimer\u2019s disease: bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurol Sci. 2025;46(4):1489\u2013507.","journal-title":"Neurol Sci"},{"issue":"5","key":"4763_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s13346-022-01256-w","volume":"13","author":"P Faria","year":"2023","unstructured":"Faria P, Pacheco C, Moura RP, Sarmento B, Martins C. Multifunctional nanomedicine strategies to manage brain diseases. Drug Deliv Transl Res. 2023;13(5):1322\u201342.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"4763_CR35","doi-asserted-by":"publisher","first-page":"2301127","DOI":"10.1002\/smtd.202301127","volume":"8","author":"S He","year":"2024","unstructured":"He S, Gou X, Zhang S, Zhang X, Huang H, Wang W, et al. Nanodelivery systems as a novel strategy to overcome treatment failure of cancer. Small Method. 2024;8(1):2301127.","journal-title":"Small Method"},{"issue":"30","key":"4763_CR36","doi-asserted-by":"publisher","first-page":"32606","DOI":"10.1021\/acsomega.5c02206","volume":"10","author":"E Kirit","year":"2025","unstructured":"Kirit E, Gokce C, Altun B, Yilmazer A. Nanotherapeutic strategies for overcoming the blood-brain barrier: applications in disease modeling and drug delivery. ACS Omega. 2025;10(30):32606\u201325.","journal-title":"ACS Omega"},{"issue":"2","key":"4763_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12013-024-01248-2","volume":"82","author":"BE Ekundayo","year":"2024","unstructured":"Ekundayo BE, Obafemi TO, Adewale OB, Obafemi BA, Oyinloye BE, Ekundayo SK. Oxidative stress, endoplasmic reticulum stress and apoptosis in the pathology of Alzheimer\u2019s disease. Cell Biochem Biophys. 2024;82(2):457\u201377.","journal-title":"Cell Biochem Biophys"},{"issue":"22","key":"4763_CR38","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.3390\/molecules25225336","volume":"25","author":"AA Khan","year":"2020","unstructured":"Khan AA, Allemailem KS, Almatroudi A, Almatroodi SA, Mahzari A, Alsahli MA, et al. Endoplasmic reticulum stress provocation by different nanoparticles: an innovative approach to manage the cancer and other common diseases. Molecules. 2020;25(22):5336.","journal-title":"Molecules"},{"issue":"39","key":"4763_CR39","doi-asserted-by":"publisher","first-page":"2405255","DOI":"10.1002\/adfm.202405255","volume":"34","author":"D Lin","year":"2024","unstructured":"Lin D, Li M, Wang L, Cheng J, Yang Y, Wang H, et al. Multifunctional hydrogel based on silk fibroin promotes tissue repair and regeneration. Adv Func Mater. 2024;34(39):2405255.","journal-title":"Adv Func Mater"},{"key":"4763_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.936897","volume":"16","author":"DK Valappil","year":"2022","unstructured":"Valappil DK, Mini NJ, Dilna A, Nath S. Membrane interaction to intercellular spread of pathology in Alzheimer\u2019s disease. Front Neurosci. 2022;16:936897.","journal-title":"Front Neurosci"},{"key":"4763_CR41","doi-asserted-by":"crossref","unstructured":"Zhao J, Chen Y, Wu Q, Wu M, Wu S, Ouyang W, et al. Mechanisms of engineered cell membrane technology and its applications in tumor and non-tumor diseases. Authorea Preprints. 2025.","DOI":"10.22541\/au.175100817.71275086\/v1"},{"issue":"1","key":"4763_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1872210517666230718115651","volume":"19","author":"A Singh","year":"2025","unstructured":"Singh A, Patel A, Chaudhary H, Yadav K, Minocha N. Nanotheranostics: the fabrication of theranostics with nanoparticles and their application to treat the neurological disorders. Recent Pat Nanotechnol. 2025;19(1):17\u201334.","journal-title":"Recent Pat Nanotechnol"},{"issue":"2","key":"4763_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/jdad2020017","volume":"2","author":"AE Alkhalifa","year":"2025","unstructured":"Alkhalifa AE, Alkhalifa O, Durdanovic I, Ibrahim DR, Maragkou S. Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease: insights into pathophysiology and treatment. J Dement Alzheimer\u2019s Dis. 2025;2(2):17.","journal-title":"J Dement Alzheimer\u2019s Dis"},{"key":"4763_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101619","volume":"77","author":"R Bai","year":"2022","unstructured":"Bai R, Guo J, Ye X-Y, Xie Y, Xie T. Oxidative stress: the core pathogenesis and mechanism of Alzheimer\u2019s disease. Ageing Res Rev. 2022;77:101619.","journal-title":"Ageing Res Rev"},{"key":"4763_CR45","doi-asserted-by":"crossref","unstructured":"Fathima SA, Maurya R, Naqvi S. Oxidative Stress and Metals in Alzheimer\u2019s Disease. Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease: Therapeutic & Theranostic Agents: Springer; 2023. p. 17\u201341.","DOI":"10.1007\/978-981-99-6038-5_2"},{"key":"4763_CR46","first-page":"680","volume":"22","author":"H Bayesteh","year":"2022","unstructured":"Bayesteh H, Mohammadpour A, Sahebanmaleki M, Moavensaidi M, Shayan SK. Effect of intravenous injection of aminophylline on rapid reduction of headache caused by spinal anesthesia. J Pharm Negat Results. 2022;22:680\u20133.","journal-title":"J Pharm Negat Results"},{"issue":"1","key":"4763_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-021-00465-0","volume":"16","author":"MM Rahman","year":"2021","unstructured":"Rahman MM, Lendel C. Extracellular protein components of amyloid plaques and their roles in Alzheimer\u2019s disease pathology. Mol Neurodegener. 2021;16(1):59.","journal-title":"Mol Neurodegener"},{"key":"4763_CR48","doi-asserted-by":"publisher","first-page":"1432002","DOI":"10.3389\/fncel.2024.1432002","volume":"18","author":"SSK Durairajan","year":"2024","unstructured":"Durairajan SSK, Selvarasu K, Singh AK, Patnaik S, Iyaswamy A, Jaiswal Y, et al. Unraveling the interplay of kinesin-1, tau, and microtubules in neurodegeneration associated with Alzheimer\u2019s disease. Front Cell Neurosci. 2024;18:1432002.","journal-title":"Front Cell Neurosci"},{"issue":"17","key":"4763_CR49","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1021\/acschemneuro.3c00486","volume":"14","author":"RG Roy","year":"2023","unstructured":"Roy RG, Mandal PK, Maroon JC. Oxidative stress occurs prior to amyloid A\u03b2 plaque formation and tau phosphorylation in Alzheimer\u2019s disease: Role of glutathione and metal ions. ACS Chem Neurosci. 2023;14(17):2944\u201354.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"4763_CR50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/13872877251340999","volume":"106","author":"F Alishahi","year":"2025","unstructured":"Alishahi F, Beam CR, Gatz M, Schneider LS, Nation DA, Yassine HN, et al. High precision and cost-effective multiplex quantification of amyloid-\u03b240, amyloid-\u03b242, p181Tau, p217Tau, neurofilament light chain, and glial fibrillary acidic protein from plasma and serum. J Alzheimer\u2019s Dis. 2025;106(2):739\u201355.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"12","key":"4763_CR51","doi-asserted-by":"publisher","first-page":"10916","DOI":"10.1007\/s12035-024-04256-8","volume":"61","author":"R Singh","year":"2024","unstructured":"Singh R, Panghal A, Jadhav K, Thakur A, Verma RK, Singh C, et al. Recent advances in targeting transition metals (Copper, iron, and Zinc) in Alzheimer\u2019s disease. Mol Neurobiol. 2024;61(12):10916\u201340.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4763_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-020-00189-z","volume":"9","author":"L Wang","year":"2020","unstructured":"Wang L, Yin Y-L, Liu X-Z, Shen P, Zheng Y-G, Lan X-R, et al. Current understanding of metal ions in the pathogenesis of Alzheimer\u2019s disease. Translat Neurodegen. 2020;9(1):10.","journal-title":"Translat Neurodegen"},{"issue":"5","key":"4763_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/1533317515622283","volume":"31","author":"X Shi","year":"2016","unstructured":"Shi X, Lin X, Hu R, Sun N, Hao J, Gao C. Toxicological differences between NMDA receptor antagonists and cholinesterase inhibitors. Am J Alzheimers Dis Other Demen. 2016;31(5):405\u201312.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"2","key":"4763_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/polym15020318","volume":"15","author":"A Al-Jipouri","year":"2023","unstructured":"Al-Jipouri A, Almurisi SH, Al-Japairai K, Bakar LM, Doolaanea AA. Liposomes or extracellular vesicles: a comprehensive comparison of both lipid bilayer vesicles for pulmonary drug delivery. Polymers. 2023;15(2):318.","journal-title":"Polymers"},{"key":"4763_CR55","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s436774","author":"C Gao","year":"2023","unstructured":"Gao C, Liu Y, Zhang T-L, Luo Y, Gao J, Chu J-J, et al. Biomembrane-derived nanoparticles in alzheimer\u2019s disease therapy: a comprehensive review of synthetic lipid nanoparticles and natural cell-derived vesicles. Int J Nanomedicine. 2023. https:\/\/doi.org\/10.2147\/ijn.s436774.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"4763_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10534-021-00360-7","volume":"35","author":"LJM Bandaru","year":"2022","unstructured":"Bandaru LJM, Ayyalasomayajula N, Murumulla L, Challa S. Mechanisms associated with the dysregulation of mitochondrial function due to lead exposure and possible implications on the development of Alzheimer\u2019s disease. Biometals. 2022;35(1):1\u201325.","journal-title":"Biometals"},{"issue":"14","key":"4763_CR57","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.3390\/nu17142266","volume":"17","author":"ZM Hein","year":"2025","unstructured":"Hein ZM, Arbain MFF, Kumar S, Mehat MZ, Hamid HA, Che Ramli MD, et al. Intermittent fasting as a neuroprotective strategy: gut-brain axis modulation and metabolic reprogramming in neurodegenerative disorders. Nutrients. 2025;17(14):2266.","journal-title":"Nutrients"},{"issue":"4","key":"4763_CR58","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/med.22034","volume":"44","author":"X Qin","year":"2024","unstructured":"Qin X, Li H, Zhao H, Fang L, Wang X. Enhancing healthy aging with small molecules: a mitochondrial perspective. Med Res Rev. 2024;44(4):1904\u201322.","journal-title":"Med Res Rev"},{"issue":"5","key":"4763_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4085","volume":"42","author":"F Hadi","year":"2024","unstructured":"Hadi F, Mortaja M, Hadi Z. Calcium (Ca2+) hemostasis, mitochondria, autophagy, and mitophagy contribute to Alzheimer\u2019s disease as early moderators. Cell Biochem Funct. 2024;42(5):e4085.","journal-title":"Cell Biochem Funct"},{"issue":"3","key":"4763_CR60","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.7150\/ijbs.103028","volume":"21","author":"Y Kim","year":"2025","unstructured":"Kim Y, Ha T-Y, Lee M-S, Chang K-A. Regulatory mechanisms and therapeutic implications of lysosomal dysfunction in Alzheimer\u2019s disease. Int J Biol Sci. 2025;21(3):1014.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"4763_CR61","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10571-022-01269-6","volume":"43","author":"X Cheng","year":"2023","unstructured":"Cheng X, Wei Y, Qian Z, Han L. Autophagy balances neuroinflammation in Alzheimer\u2019s disease. Cell Mol Neurobiol. 2023;43(4):1537\u201349.","journal-title":"Cell Mol Neurobiol"},{"issue":"3","key":"4763_CR62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/jdad2030029","volume":"2","author":"E Erdag","year":"2025","unstructured":"Erdag E, Haskologlu IC. Microglial neuroinflammation in Alzheimer\u2019s disease: mechanisms and therapies. J Dement Alzheimer\u2019s Dis. 2025;2(3):29.","journal-title":"J Dement Alzheimer's Dis"},{"issue":"12","key":"4763_CR63","doi-asserted-by":"publisher","first-page":"2300180","DOI":"10.1002\/advs.202300180","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen H, Zhang W, Liu Y, Ding L, Gong J, et al. Biomimetic remodeling of microglial riboflavin metabolism ameliorates cognitive impairment by modulating neuroinflammation. Adv Sci. 2023;10(12):2300180.","journal-title":"Adv Sci"},{"issue":"5","key":"4763_CR64","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s11596-023-2788-4","volume":"43","author":"YR Jia","year":"2023","unstructured":"Jia YR, Guo ZQ, Guo Q, Wang XC. Glycogen synthase kinase-3\u03b2, NLRP3 inflammasome, and Alzheimer\u2019s disease. Curr Med Sci. 2023;43(5):847\u201354.","journal-title":"Curr Med Sci."},{"issue":"1","key":"4763_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10753-022-01730-0","volume":"46","author":"B Sharma","year":"2023","unstructured":"Sharma B, Satija G, Madan A, Garg M, Alam MM, Shaquiquzzaman M, et al. Role of NLRP3 inflammasome and its inhibitors as emerging therapeutic drug candidate for Alzheimer\u2019s disease: a review of mechanism of activation, regulation, and inhibition. Inflammation. 2023;46(1):56\u201387.","journal-title":"Inflammation"},{"issue":"10","key":"4763_CR66","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1039\/D4NH00171K","volume":"9","author":"KD Patel","year":"2024","unstructured":"Patel KD, Keskin-Erdogan Z, Sawadkar P, Sharifulden NSAN, Shannon MR, Patel M, et al. Oxidative stress modulating nanomaterials and their biochemical roles in nanomedicine. Nanoscale horizons. 2024;9(10):1630\u201382.","journal-title":"Nanoscale horizons"},{"issue":"21","key":"4763_CR67","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH. Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci. 2022;23(21):12841.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4763_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103487","volume":"28","author":"KB Moore","year":"2023","unstructured":"Moore KB, Hung T-J, Fortin JS. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer\u2019s disease and related tauopathies. Drug Discov Today. 2023;28(3):103487.","journal-title":"Drug Discov Today"},{"issue":"4","key":"4763_CR69","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"4763_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21(1):e14338.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"4763_CR71","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"4763_CR72","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci M, Chiotis K, Nordberg A. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26(10):5888\u201398.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"4763_CR73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","volume":"6","author":"GB Frisoni","year":"2010","unstructured":"Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67\u201377.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"4763_CR74","doi-asserted-by":"publisher","first-page":"e08901","DOI":"10.1016\/j.heliyon.2022.e08901","volume":"8","author":"R Mohtasib","year":"2022","unstructured":"Mohtasib R, Alghamdi J, Jobeir A, Masawi A, De Barros NP, Billiet T, et al. MRI biomarkers for Alzheimer\u2019s disease: the impact of functional connectivity in the default mode network and structural connectivity between lobes on diagnostic accuracy. Heliyon. 2022;8(2):e08901.","journal-title":"Heliyon."},{"issue":"6","key":"4763_CR75","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuron.2020.06.004","volume":"106","author":"H Zetterberg","year":"2020","unstructured":"Zetterberg H, Blennow K. Blood biomarkers: democratizing Alzheimer\u2019s diagnostics. Neuron. 2020;106(6):881\u20133.","journal-title":"Neuron"},{"issue":"9","key":"4763_CR76","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/alz.12316","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson O, Batrla R, Brix B, Carrillo MC, Corradini V, Edelmayer RM, et al. The Alzheimer\u2019s association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimers Dement. 2021;17(9):1575\u201382.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"4763_CR77","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"11","key":"4763_CR78","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol"},{"issue":"5","key":"4763_CR79","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319.","journal-title":"Nat Aging"},{"issue":"3","key":"4763_CR80","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"4763_CR81","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules25092193","volume":"25","author":"AA Yetisgin","year":"2020","unstructured":"Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.","journal-title":"Molecules"},{"issue":"1","key":"4763_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211.","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"4763_CR83","doi-asserted-by":"publisher","first-page":"2308239","DOI":"10.1002\/adma.202308239","volume":"36","author":"X Long","year":"2024","unstructured":"Long X, Liu M, Nan Y, Chen Q, Xiao Z, Xiang Y, et al. Revitalizing ancient mitochondria with nano-strategies: mitochondria-remedying nanodrugs concentrate on disease control. Adv Mater. 2024;36(18):2308239.","journal-title":"Adv Mater"},{"issue":"15","key":"4763_CR84","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.3390\/ijms26157498","volume":"26","author":"M \u0218erban","year":"2025","unstructured":"\u0218erban M, Toader C, Covache-Busuioc R-A. The Redox revolution in brain medicine: targeting oxidative stress with AI, multi-omics and mitochondrial therapies for the precision eradication of neurodegeneration. Int J Mol Sci. 2025;26(15):7498.","journal-title":"Int J Mol Sci"},{"key":"4763_CR85","first-page":"93","volume-title":"Nanoparticles in tissue engineering application and regenerative medicine","author":"SK Chinnaiyan","year":"2024","unstructured":"Chinnaiyan SK, Arthanari S, Subramanian M. Nanoparticles in tissue engineering application and regenerative medicine. Introduction to functional nanomaterials: CRC Press; 2024. p. 93\u2013119."},{"issue":"5","key":"4763_CR86","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/anie.201915826","volume":"60","author":"SS Liew","year":"2021","unstructured":"Liew SS, Qin X, Zhou J, Li L, Huang W, Yao SQ. Smart design of nanomaterials for mitochondria-targeted nanotherapeutics. Angew Chem Int Ed. 2021;60(5):2232\u201356.","journal-title":"Angew Chem Int Ed"},{"issue":"2","key":"4763_CR87","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4103\/NRR.NRR-D-23-01736","volume":"20","author":"M Hao","year":"2025","unstructured":"Hao M, Chu J, Zhang T, Yin T, Gu Y, Liang W, et al. Nanomaterials-mediated lysosomal regulation: a robust protein-clearance approach for the treatment of Alzheimer\u2019s disease. Neural Regen Res. 2025;20(2):424\u201339.","journal-title":"Neural Regen Res"},{"key":"4763_CR88","doi-asserted-by":"publisher","first-page":"e04435","DOI":"10.1002\/adma.202504435","volume":"37","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang Y, Liang R, Zou J, Pei R, Chen X. Targeted ROS scavenging for disease therapies using nanomaterials. Adv Mater. 2025;37:e04435.","journal-title":"Adv Mater"},{"issue":"9","key":"4763_CR89","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/antiox13091138","volume":"13","author":"T Gogna","year":"2024","unstructured":"Gogna T, Housden BE, Houldsworth A. Exploring the role of reactive oxygen species in the pathogenesis and pathophysiology of Alzheimer\u2019s and Parkinson\u2019s disease and the efficacy of antioxidant treatment. Antioxidants. 2024;13(9):1138.","journal-title":"Antioxidants"},{"key":"4763_CR90","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s516260","author":"S-H Wang","year":"2025","unstructured":"Wang S-H, Xu X-L, Chen W. How do organelle-targeting nanotherapeutics treat inflammatory diseases? A comprehensive review of the literature. Int J Nanomed. 2025. https:\/\/doi.org\/10.2147\/ijn.s516260.","journal-title":"Int J Nanomed"},{"key":"4763_CR91","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s529127","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wen P, Zhang B-F, Hu S, Yang Z. Nano-drug delivery system targeting the oxidative stress microenvironment: a prospective strategy for intervertebral disc degeneration treatment. Int J Nanomed. 2025. https:\/\/doi.org\/10.2147\/ijn.s529127.","journal-title":"Int J Nanomed"},{"issue":"15","key":"4763_CR92","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1039\/D4CS00421C","volume":"53","author":"JC Hsu","year":"2024","unstructured":"Hsu JC, Liu P, Song Y, Song W, Saladin RJ, Peng Y, et al. Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond. Chem Soc Rev. 2024;53(15):7657\u201380.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"4763_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-001079","volume":"7","author":"I Cani","year":"2025","unstructured":"Cani I, Grotteschi N, Calandra-Buonaura G, Guarino M, Guaraldi P, Giannini G, et al. Efficacy of cholinesterase inhibitors and memantine on symptoms not responsive to levodopa in patients affected by Parkinson\u2019s disease without dementia: a systematic review. BMJ Neurol Open. 2025;7(2):e001079.","journal-title":"BMJ Neurol Open"},{"issue":"10","key":"4763_CR94","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/nano15100704","volume":"15","author":"CH Lo","year":"2025","unstructured":"Lo CH, Cheong LYT, Zeng J. Nanoplatforms targeting intrinsically disordered protein aggregation for translational neuroscience applications. Nanomaterials. 2025;15(10):704.","journal-title":"Nanomaterials"},{"issue":"9","key":"4763_CR95","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1039\/D5BM00179J","volume":"13","author":"S Sabnam","year":"2025","unstructured":"Sabnam S, Kumar R. Biofunctionalized nanomaterials for Parkinson\u2019s disease theranostics: potential for efficient PD biomarker detection and effective therapy. Biomater Sci. 2025;13(9):2201\u201334.","journal-title":"Biomater Sci"},{"issue":"38","key":"4763_CR96","doi-asserted-by":"publisher","first-page":"2403473","DOI":"10.1002\/advs.202403473","volume":"11","author":"Q Song","year":"2024","unstructured":"Song Q, Li J, Li T, Li HW. Nanomaterials that aid in the diagnosis and treatment of Alzheimer\u2019s disease, resolving blood\u2013brain barrier crossing ability. Adv Sci. 2024;11(38):2403473.","journal-title":"Adv Sci"},{"issue":"2","key":"4763_CR97","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1381612827666211122153946","volume":"28","author":"P Tripathi","year":"2022","unstructured":"Tripathi P, Shukla P, Bieberich E. Theranostic applications of nanomaterials in Alzheimer\u2019s disease: a multifunctional approach. Curr Pharm Des. 2022;28(2):116\u201332.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"4763_CR98","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1039\/D3MH00592E","volume":"10","author":"Z Yan","year":"2023","unstructured":"Yan Z, Liu Y, Zhao L, Hu J, Du Y, Peng X, et al. In situ stimulus-responsive self-assembled nanomaterials for drug delivery and disease treatment. Mater Horiz. 2023;10(9):3197\u2013217.","journal-title":"Mater Horiz"},{"issue":"3","key":"4763_CR99","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.apsb.2026.01.019","volume":"16","author":"X Zhang","year":"2026","unstructured":"Zhang X, Jing H, Wang Y, Mu S, Wang X, Zheng H, et al. Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: advances and outlook. Acta Pharm Sin B. 2026;16(3):1388\u2013420.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"4763_CR100","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RN Lamptey","year":"2022","unstructured":"Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23(3):1851.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4763_CR101","doi-asserted-by":"publisher","first-page":"2406324","DOI":"10.1002\/advs.202406324","volume":"12","author":"A Rafieerad","year":"2025","unstructured":"Rafieerad A, Saleth LR, Khanahmadi S, Amiri A, Alagarsamy KN, Dhingra S. Periodic table of immunomodulatory elements and derived two-dimensional biomaterials. Adv Sci. 2025;12(6):2406324.","journal-title":"Adv Sci"},{"issue":"4","key":"4763_CR102","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4103\/NRR.NRR-D-24-01507","volume":"21","author":"M Zhou","year":"2026","unstructured":"Zhou M, Zheng M, Liang S, Li M, Ma J, Zhang S, et al. Inherent potential of mitochondria-targeted interventions for chronic neurodegenerative diseases. Neural Regen Res. 2026;21(4):1409\u201327.","journal-title":"Neural Regen Res"},{"issue":"18","key":"4763_CR103","doi-asserted-by":"publisher","first-page":"10920","DOI":"10.1021\/acs.chemrev.3c00062","volume":"123","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Xiang J, Qiu N, Wang Y, Piao Y, Shao S, et al. Tumor abnormality-oriented nanomedicine design. Chem Rev. 2023;123(18):10920\u201389.","journal-title":"Chem Rev"},{"issue":"21","key":"4763_CR104","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1039\/D4CC06501H","volume":"61","author":"J Tang","year":"2025","unstructured":"Tang J, Li D, Wang R, Li S, Xing Y, Yu F. Engineered extracellular vesicles: an emerging nanomedicine therapeutic platform. Chem Commun. 2025;61(21):4123\u201346.","journal-title":"Chem Commun"},{"key":"4763_CR105","unstructured":"\uc624\uc608\ub098. Immune modulating nanomedicine for cancer metabolism reprogramming and rheumatoid arthritis vaccination: \uc11c\uc6b8\ub300\ud559\uad50 \ub300\ud559\uc6d0; 2023."},{"key":"4763_CR106","doi-asserted-by":"publisher","first-page":"1228679","DOI":"10.3389\/fcell.2023.1228679","volume":"11","author":"L Hu","year":"2023","unstructured":"Hu L, Tao Y, Jiang Y, Qin F. Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol. 2023;11:1228679.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4763_CR107","doi-asserted-by":"publisher","first-page":"20230137","DOI":"10.1002\/EXP.20230137","volume":"5","author":"S Pawar","year":"2025","unstructured":"Pawar S, Rauf MA, Abdelhady H, Iyer AK. Tau-targeting nanoparticles for treatment of Alzheimer\u2019s disease. Exploration (Beijing). 2025;5(2):20230137.","journal-title":"Exploration (Beijing)"},{"key":"4763_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/cells14120911","author":"ZM Hein","year":"2025","unstructured":"Hein ZM, Vishnumukkala T, Karikalan B, Alkatiri A, Hussan F, Jagadeesan S, et al. Autophagy and Alzheimer\u2019s disease: mechanisms and impact beyond the brain. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14120911.","journal-title":"Cells"},{"issue":"1","key":"4763_CR109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12035-025-05417-z","volume":"63","author":"U Kochman","year":"2025","unstructured":"Kochman U, Sitka H, Ku\u017aniar J, Czaja M, Kozubek P, Besz\u0142ej JA, et al. Targeted nanoparticles for drug delivery across the blood-brain barrier in early and late stages of Alzheimer\u2019s disease: a review. Mol Neurobiol. 2025;63(1):75.","journal-title":"Mol Neurobiol"},{"key":"4763_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114426","volume":"389","author":"G Wang","year":"2026","unstructured":"Wang G, Wang N, Xia X, Ismail M, Shi B. Clinical translation of nanomedicines for brain diseases: current challenges and future directions. J Control Release. 2026;389:114426.","journal-title":"J Control Release"},{"issue":"3","key":"4763_CR111","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2022","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, Carreira B, Pozzi S, Ac\u00farcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500\u201325.","journal-title":"Drug Deliv Transl Res"},{"key":"4763_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082042","author":"HB Koh","year":"2023","unstructured":"Koh HB, Kim HJ, Kang SW, Yoo TH. Exosome-based drug delivery: translation from bench to clinic. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15082042.","journal-title":"Pharmaceutics"},{"key":"4763_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236056","author":"JW Shreffler","year":"2019","unstructured":"Shreffler JW, Pullan JE, Dailey KM, Mallik S, Brooks AE. Overcoming hurdles in nanoparticle clinical translation: the influence of experimental design and surface modification. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20236056.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4763_CR114","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1208\/s12249-026-03425-3","volume":"27","author":"A Shadab","year":"2026","unstructured":"Shadab A, Haider MF, Abohassan M. Liposome-based drug delivery systems: mechanisms, preparation strategies, clinical status, and therapeutic applications. AAPS PharmSciTech. 2026;27(4):190.","journal-title":"AAPS PharmSciTech"},{"key":"4763_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1591438","author":"K Wang","year":"2025","unstructured":"Wang K, Yang R, Li J, Wang H, Wan L, He J. Nanocarrier-based targeted drug delivery for Alzheimer\u2019s disease: addressing neuroinflammation and enhancing clinical translation. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1591438.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4763_CR116","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.14336\/AD.2022.0130-1","volume":"13","author":"QQ Tao","year":"2022","unstructured":"Tao QQ, Lin RR, Chen YH, Wu ZY. Discerning the role of blood brain barrier dysfunction in Alzheimer\u2019s disease. Aging Dis. 2022;13(5):1391\u2013404.","journal-title":"Aging Dis"},{"issue":"12","key":"4763_CR117","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1016\/j.xphs.2024.09.005","volume":"113","author":"JD Clogston","year":"2024","unstructured":"Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, et al. Current state of nanomedicine drug products: an industry perspective. J Pharm Sci. 2024;113(12):3395\u2013405.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4763_CR118","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Bendlin BB. Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26(1):296\u2013308.","journal-title":"Mol Psychiatry"},{"key":"4763_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.109941","volume":"252","author":"RM McManus","year":"2024","unstructured":"McManus RM, Latz E. NLRP3 inflammasome signalling in Alzheimer\u2019s disease. Neuropharmacology. 2024;252:109941.","journal-title":"Neuropharmacology"},{"issue":"47","key":"4763_CR120","doi-asserted-by":"publisher","first-page":"36958","DOI":"10.1074\/jbc.M110.127829","volume":"285","author":"TL Lewis","year":"2010","unstructured":"Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem. 2010;285(47):36958\u201368.","journal-title":"J Biol Chem"},{"key":"4763_CR121","doi-asserted-by":"publisher","DOI":"10.61373\/gp025i.0122","author":"F Tang","year":"2025","unstructured":"Tang F, Wei J, Wong ML, Lei P. Tau protein: physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders. Genomic Psychiatry. 2025. https:\/\/doi.org\/10.61373\/gp025i.0122.","journal-title":"Genomic Psychiatry"},{"issue":"4","key":"4763_CR122","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1039\/D2MD00397J","volume":"14","author":"M Failla","year":"2023","unstructured":"Failla M, Floresta G, Abbate V. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling. RSC medicinal chemistry. 2023;14(4):592\u2013623.","journal-title":"RSC medicinal chemistry"},{"key":"4763_CR123","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.nucmedbio.2020.11.006","volume":"93","author":"M Rosestedt","year":"2021","unstructured":"Rosestedt M, Velikyan I, Rosenstr\u00f6m U, Estrada S, \u00c5berg O, Weis J, et al. Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 1. Nucl Med Biol. 2021;93:54\u201362.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"4763_CR124","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-019-0837-9","volume":"7","author":"DR Thal","year":"2019","unstructured":"Thal DR, Ronisz A, Tousseyn T, Rijal Upadhaya A, Balakrishnan K, Vandenberghe R, et al. Different aspects of Alzheimer\u2019s disease-related amyloid \u03b2-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathol Commun. 2019;7(1):178.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4763_CR125","doi-asserted-by":"publisher","first-page":"17","DOI":"10.15302\/J-QB-021-0271","volume":"10","author":"L Zhu","year":"2022","unstructured":"Zhu L, Qian Z. Recent studies of atomic\u2010resolution structures of tau protein and structure\u2010based inhibitors. Quantitative Biology. 2022;10(1):17\u201334.","journal-title":"Quantitative Biology"},{"issue":"6","key":"4763_CR126","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/biom15060831","volume":"15","author":"G Jiang","year":"2025","unstructured":"Jiang G, Xie G, Li X, Xiong J. Cytoskeletal proteins and Alzheimer\u2019s disease pathogenesis: focusing on the Interplay with Tau pathology. Biomolecules. 2025;15(6):831.","journal-title":"Biomolecules"},{"issue":"11","key":"4763_CR127","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41580-024-00757-5","volume":"25","author":"RA Nixon","year":"2024","unstructured":"Nixon RA, Rubinsztein DC. Mechanisms of autophagy\u2013lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25(11):926\u201346.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"4763_CR128","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.apsb.2025.01.015","volume":"15","author":"Y Wei","year":"2025","unstructured":"Wei Y, Xia X, Wang X, Yang W, He S, Wang L, et al. Enhanced BBB penetration and microglia-targeting nanomodulator for the two-pronged modulation of chronically activated microglia-mediated neuroinflammation in Alzheimer\u2019s disease. Acta Pharmaceutica Sinica B. 2025;15(2):1098\u2013111.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"4763_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122749","volume":"312","author":"A Xie","year":"2025","unstructured":"Xie A, Cheng G, Wu J, Li Z, Yu G, Zhu X, et al. Highly BBB-permeable nanomedicine reverses neuroapoptosis and neuroinflammation to treat Alzheimer\u2019s disease. Biomaterials. 2025;312:122749.","journal-title":"Biomaterials"},{"key":"4763_CR130","unstructured":"Chen J. Nanomedicine modulation of endothelial low-density lipoprotein receptor-related protein 1 at the blood\u2013brain barrier for Alzheimer's disease therapy [PhD thesis]. London (UK): University College London; 2025. Available from: UCL Discovery Repository."},{"key":"4763_CR131","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S442775","author":"S Shi","year":"2024","unstructured":"Shi S, Ou X, Cheng D. Nanoparticle-facilitated therapy: advancing tools in peripheral nerve regeneration. Int J Nanomed. 2024. https:\/\/doi.org\/10.2147\/IJN.S442775.","journal-title":"Int J Nanomed"},{"issue":"7","key":"4763_CR132","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/pharmaceutics16070849","volume":"16","author":"F Susa","year":"2024","unstructured":"Susa F, Arpicco S, Pirri CF, Limongi T. An overview on the physiopathology of the Blood-Brain barrier and the Lipid-Based nanocarriers for central nervous system delivery. Pharmaceutics. 2024;16(7):849.","journal-title":"Pharmaceutics"},{"issue":"5","key":"4763_CR133","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10989-023-10558-7","volume":"29","author":"H Thamarai Kannan","year":"2023","unstructured":"Thamarai Kannan H, Issac PK, Dey N, Guru A, Arockiaraj J. A review on mitochondrial derived peptide humanin and small humanin-like peptides and their therapeutic strategies. Int J Pept Res Ther. 2023;29(5):86.","journal-title":"Int J Pept Res Ther"},{"issue":"3","key":"4763_CR134","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1021\/acsnano.0c10690","volume":"15","author":"H Sun","year":"2021","unstructured":"Sun H, Zhong Y, Zhu X, Liao H, Lee J, Chen Y, et al. A tauopathy-homing and autophagy-activating nanoassembly for specific clearance of pathogenic Tau in Alzheimer\u2019s disease. ACS Nano. 2021;15(3):5263\u201375.","journal-title":"ACS Nano"},{"issue":"4","key":"4763_CR135","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/prot.24988","volume":"84","author":"TJ Malia","year":"2016","unstructured":"Malia TJ, Teplyakov A, Ernst R, Wu SJ, Lacy ER, Liu X, et al. Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. Proteins. 2016;84(4):427\u201334.","journal-title":"Proteins"},{"issue":"3","key":"4763_CR136","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0304-3940(95)11484-E","volume":"189","author":"M Goedert","year":"1995","unstructured":"Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189(3):167\u20139.","journal-title":"Neurosci Lett"},{"issue":"6","key":"4763_CR137","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"CF Xia","year":"2013","unstructured":"Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimers Dement. 2013;9(6):666\u201376.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"4763_CR138","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","volume":"38","author":"DT Chien","year":"2014","unstructured":"Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38(1):171\u201384.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"4763_CR139","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nchem.2889","volume":"10","author":"PM Seidler","year":"2018","unstructured":"Seidler PM, Boyer DR, Rodriguez JA, Sawaya MR, Cascio D, Murray K, et al. Structure-based inhibitors of tau aggregation. Nat Chem. 2018;10(2):170\u20136.","journal-title":"Nat Chem"},{"issue":"13","key":"4763_CR140","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1021\/acs.jpcb.5b00175","volume":"119","author":"P Ganguly","year":"2015","unstructured":"Ganguly P, Do TD, Larini L, LaPointe NE, Sercel AJ, Shade MF, et al. Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3. J Phys Chem B. 2015;119(13):4582\u201393.","journal-title":"J Phys Chem B"},{"issue":"39","key":"4763_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202313869","volume":"36","author":"L Xu","year":"2024","unstructured":"Xu L, Wu X, Zhao S, Hu H, Wang S, Zhang Y, et al. Harnessing nanochaperone-mediated autophagy for selective clearance of pathogenic Tau protein in Alzheimer\u2019s disease. Adv Mater. 2024;36(39):e2313869.","journal-title":"Adv Mater"},{"issue":"9","key":"4763_CR142","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1007\/s11064-016-1960-7","volume":"41","author":"H Bian","year":"2016","unstructured":"Bian H, Bian W, Lin X, Ma Z, Chen W, Pu Y. RNA interference silencing of glycogen synthase kinase 3\u03b2 Inhibites Tau phosphorylation in mice with alzheimer disease. Neurochem Res. 2016;41(9):2470\u201380.","journal-title":"Neurochem Res"},{"issue":"6","key":"4763_CR143","doi-asserted-by":"publisher","first-page":"9936","DOI":"10.1002\/jcb.28276","volume":"120","author":"J Li","year":"2019","unstructured":"Li J, Chen W, Yi Y, Tong Q. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3\u03b2 in Alzheimer\u2019s disease. J Cell Biochem. 2019;120(6):9936\u201346.","journal-title":"J Cell Biochem"},{"key":"4763_CR144","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jcis.2022.01.051","volume":"613","author":"A Mazzaglia","year":"2022","unstructured":"Mazzaglia A, Di Natale G, Tosto R, Scala A, Sortino G, Piperno A, et al. KLVFF oligopeptide-decorated amphiphilic cyclodextrin nanomagnets for selective amyloid beta recognition and fishing. J Colloid Interface Sci. 2022;613:814\u201326.","journal-title":"J Colloid Interface Sci"},{"key":"4763_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11110572","author":"F Pederzoli","year":"2019","unstructured":"Pederzoli F, Ruozi B, Duskey J, Hagmeyer S, Sauer AK, Grabrucker S, et al. Nanomedicine against A\u03b2 aggregation by \u03b2-sheet breaker peptide delivery: in vitro evidence. Pharmaceutics. 2019. https:\/\/doi.org\/10.3390\/pharmaceutics11110572.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4763_CR146","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/nn4058215","volume":"8","author":"Q Song","year":"2014","unstructured":"Song Q, Huang M, Yao L, Wang X, Gu X, Chen J, et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer\u2019s disease by accelerating the clearance of amyloid-beta. ACS Nano. 2014;8(3):2345\u201359.","journal-title":"ACS Nano"},{"issue":"11","key":"4763_CR147","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1021\/acs.molpharmaceut.6b00781","volume":"13","author":"Q Song","year":"2016","unstructured":"Song Q, Song H, Xu J, Huang J, Hu M, Gu X, et al. Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood-brain barrier penetration and amyloid beta-targeting drug delivery. Mol Pharm. 2016;13(11):3976\u201387.","journal-title":"Mol Pharm"},{"key":"4763_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc7031","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhu F, Liu Y, Zheng M, Wang Y, Zhang D, et al. Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.abc7031.","journal-title":"Sci Adv"},{"key":"4763_CR149","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","volume":"279","author":"P Wang","year":"2018","unstructured":"Wang P, Zheng X, Guo Q, Yang P, Pang X, Qian K, et al. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease. J Control Release. 2018;279:220\u201333.","journal-title":"J Control Release"},{"key":"4763_CR150","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jconrel.2023.12.030","volume":"366","author":"J Gu","year":"2024","unstructured":"Gu J, Yan C, Yin S, Wu H, Liu C, Xue A, et al. Erythrocyte membrane-coated nanocarriers modified by TGN for Alzheimer\u2019s disease. J Control Release. 2024;366:448\u201359.","journal-title":"J Control Release"},{"issue":"24","key":"4763_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306675","volume":"11","author":"RR Lin","year":"2024","unstructured":"Lin RR, Jin LL, Xue YY, Zhang ZS, Huang HF, Chen DF, et al. Hybrid membrane-coated nanoparticles for precise targeting and synergistic therapy in Alzheimer\u2019s disease. Adv Sci. 2024;11(24):e2306675.","journal-title":"Adv Sci"},{"issue":"36","key":"4763_CR152","doi-asserted-by":"publisher","first-page":"12576","DOI":"10.1021\/acs.langmuir.3c01169","volume":"39","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu W, Dong X, Sun Y. Design of self-assembled nanoparticles as a potent inhibitor and fluorescent probe for \u03b2-amyloid fibrillization. Langmuir. 2023;39(36):12576\u201389.","journal-title":"Langmuir"},{"issue":"12","key":"4763_CR153","doi-asserted-by":"publisher","first-page":"13556","DOI":"10.1021\/acsomega.3c10417","volume":"9","author":"TN Francisco","year":"2024","unstructured":"Francisco TN, Malafaia D, Melo L, Silva AMS, Albuquerque HMT. Recent advances in fluorescent theranostics for Alzheimer\u2019s disease: a comprehensive survey on design, synthesis, and properties. ACS Omega. 2024;9(12):13556\u201391.","journal-title":"ACS Omega"},{"issue":"10","key":"4763_CR154","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.70142","volume":"61","author":"F Siddiqui","year":"2025","unstructured":"Siddiqui F, Mishra P, Khanam S, Ranjan S, Alam P, Albalawi T, et al. Nano-chaperones: bridging therapeutics for amyloid aggregation in Alzheimer\u2019s disease and type-2 diabetes mellitus. Eur J Neurosci. 2025;61(10):e70142.","journal-title":"Eur J Neurosci"},{"key":"4763_CR155","unstructured":"Trainer T. Glial autophagy capability and the control of neuroinflammatory signaling in Parkinson's disease [MScR thesis]. Bristol (UK): University of Bristol; 2023. Degree: Master of Science by Research (MScR) Institution: University of Bristol Place: Bristol, United Kingdom Year: 2023Date of award: 24 January 2023 Supervisors: Jon D. Lane; Bernadette M. Carroll.  Available from:  https:\/\/research-information.bris.ac.uk\/en\/studentTheses\/glial-autophagy-capability-and-the-control-of-neuroinflammatory-s\/"},{"issue":"1","key":"4763_CR156","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41467-019-09477-3","volume":"10","author":"S De","year":"2019","unstructured":"De S, Wirthensohn DC, Flagmeier P, Hughes C, Aprile FA, Ruggeri FS, et al. Different soluble aggregates of A\u03b242 can give rise to cellular toxicity through different mechanisms. Nat Commun. 2019;10(1):1541.","journal-title":"Nat Commun"},{"issue":"6","key":"4763_CR157","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3390\/molecules29061405","volume":"29","author":"H Lan","year":"2024","unstructured":"Lan H, Wang Y, Liu W, Dong X, Sun Y. Composite of KLVFF-transthyretin-penetratin and manganese dioxide nanoclusters: a multifunctional agent against alzheimer\u2019s \u03b2-amyloid fibrillogenesis. Molecules. 2024;29(6):1405.","journal-title":"Molecules"},{"issue":"9","key":"4763_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202309958","volume":"63","author":"N Andrikopoulos","year":"2024","unstructured":"Andrikopoulos N, Tang H, Wang Y, Liang X, Li Y, Davis TP, et al. Exploring peptido-nanocomposites in the context of amyloid diseases. Angew Chem Int Ed. 2024;63(9):e202309958.","journal-title":"Angew Chem Int Ed"},{"issue":"11","key":"4763_CR159","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/biom12111676","volume":"12","author":"Z Fi\u0161ar","year":"2022","unstructured":"Fi\u0161ar Z. Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer\u2019s disease and identifying promising drug targets. Biomolecules. 2022;12(11):1676.","journal-title":"Biomolecules"},{"issue":"3","key":"4763_CR160","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/neuroglia4030014","volume":"4","author":"AM Elshazly","year":"2023","unstructured":"Elshazly AM, Sinanian MM, Elimam DM, Zakaria S. Overview of the molecular modalities and signaling pathways intersecting with \u03b2-amyloid and Tau protein in Alzheimer\u2019s disease. Neuroglia. 2023;4(3):191\u2013208.","journal-title":"Neuroglia"},{"key":"4763_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102385","volume":"35","author":"X Deng","year":"2025","unstructured":"Deng X, Liu X, Zhao L. Multifunctional nanoplatforms for tumor microenvironment remodeling: toward precision and intelligent cancer therapy. Mater Today Bio. 2025;35:102385.","journal-title":"Mater Today Bio"},{"issue":"2","key":"4763_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12589","volume":"16","author":"L Bl\u00f6meke","year":"2024","unstructured":"Bl\u00f6meke L, Rehn F, Kraemer-Schulien V, Kutzsche J, Pils M, Bujnicki T, et al. A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology. Alzheimers Dement (Amst). 2024;16(2):e12589.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"4763_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27083560","volume":"27","author":"Y Zorkina","year":"2026","unstructured":"Zorkina Y, Abramova O, Zubkov E, Gurina O, Ushakova V. Theranostic nanoplatforms for Alzheimer\u2019s disease: a critical analysis of conceptual contradictions. Int J Mol Sci. 2026;27(8):3560.","journal-title":"Int J Mol Sci"},{"issue":"36","key":"4763_CR164","doi-asserted-by":"publisher","first-page":"16962","DOI":"10.1039\/C8NR04073G","volume":"10","author":"N Poovaiah","year":"2018","unstructured":"Poovaiah N, Davoudi Z, Peng H, Schlichtmann B, Mallapragada S, Narasimhan B, et al. Treatment of neurodegenerative disorders through the blood\u2013brain barrier using nanocarriers. Nanoscale. 2018;10(36):16962\u201383.","journal-title":"Nanoscale"},{"issue":"1","key":"4763_CR165","doi-asserted-by":"publisher","first-page":"2301726","DOI":"10.1002\/adhm.202301726","volume":"13","author":"Y Shi","year":"2024","unstructured":"Shi Y, Zhang Y, Zhu L, Miao Y, Zhu Y, Yue B. Tailored drug delivery platforms: stimulus-responsive core\u2013shell structured nanocarriers. Adv Healthcare Mater. 2024;13(1):2301726.","journal-title":"Adv Healthcare Mater"},{"key":"4763_CR166","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/CIA.S155145","volume":"13","author":"VV Giau","year":"2018","unstructured":"Giau VV, Lee H, Shim KH, Bagyinszky E, An SSA. Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer\u2019s disease. Clin Interv Aging. 2018;13:221\u201333.","journal-title":"Clin Interv Aging"},{"key":"4763_CR167","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01301-8","author":"G Kaur","year":"2024","unstructured":"Kaur G, Arora J, Sodhi AS, Bhatia S, Batra N. Nanotechnology and CRISPR\/Cas-mediated gene therapy strategies: potential role for treating genetic disorders. Mol Biotechnol. 2024. https:\/\/doi.org\/10.1007\/s12033-024-01301-8.","journal-title":"Mol Biotechnol"},{"key":"4763_CR168","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/B978-0-443-23841-3.00014-5","volume-title":"Targeted Therapy for the Central Nervous System","author":"G Shareena","year":"2025","unstructured":"Shareena G, Viswalingam V, Rajput MS, Kumar D. CRISPR\/Cas9 gene editing: a new hope for Alzheimer\u2019s disease. In: Targeted Therapy for the Central Nervous System. Elsevier; 2025. p. 301\u201323."},{"issue":"13","key":"4763_CR169","doi-asserted-by":"publisher","first-page":"8307","DOI":"10.1021\/acs.chemrev.4c00009","volume":"124","author":"H Huang","year":"2024","unstructured":"Huang H, Zheng Y, Chang M, Song J, Xia L, Wu C, et al. Ultrasound-based micro-\/nanosystems for biomedical applications. Chem Rev. 2024;124(13):8307\u2013472.","journal-title":"Chem Rev"},{"issue":"6","key":"4763_CR170","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3390\/pharmaceutics14061282","volume":"14","author":"C-H Li","year":"2022","unstructured":"Li C-H, Chang Y-C, Hsiao M, Chan M-H. Ultrasound and nanomedicine for cancer-targeted drug delivery: screening, cellular mechanisms and therapeutic opportunities. Pharmaceutics. 2022;14(6):1282.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4763_CR171","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1039\/D2NA00625A","volume":"5","author":"X Shao","year":"2023","unstructured":"Shao X, Yan C, Wang C, Wang C, Cao Y, Zhou Y, et al. Advanced nanomaterials for modulating Alzheimer\u2019s related amyloid aggregation. Nanoscale Adv. 2023;5(1):46\u201380.","journal-title":"Nanoscale Adv"},{"key":"4763_CR172","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S444115","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Liu Y, Ruan S, Hu Y. Current anti-amyloid-\u03b2 therapy for Alzheimer\u2019s disease treatment: from clinical research to nanomedicine. Int J Nanomed. 2023. https:\/\/doi.org\/10.2147\/IJN.S444115.","journal-title":"Int J Nanomed"},{"key":"4763_CR173","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-025-00665-x","author":"S Das","year":"2025","unstructured":"Das S, Murumulla L, Ghosh P, Challa S. Heavy metal-induced disruption of the autophagy-lysosomal pathway: implications for aging and neurodegenerative disorders. Biometals. 2025. https:\/\/doi.org\/10.1007\/s10534-025-00665-x.","journal-title":"Biometals"},{"key":"4763_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121517","volume":"285","author":"Q Guo","year":"2022","unstructured":"Guo Q, Chen C, Wu Z, Zhang W, Wang L, Yu J, et al. Engineered PD-1\/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell\/Treg balance and alleviate systemic lupus erythematosus. Biomaterials. 2022;285:121517.","journal-title":"Biomaterials"},{"issue":"3","key":"4763_CR175","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.drudis.2020.12.004","volume":"26","author":"S Bhatt","year":"2021","unstructured":"Bhatt S, Puli L, Patil CR. Role of reactive oxygen species in the progression of Alzheimer\u2019s disease. Drug Discov Today. 2021;26(3):794\u2013803.","journal-title":"Drug Discov Today"},{"key":"4763_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/sstr.202500195","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yan J, Cui C, Xu Y, Zhang K, Du M, et al. Nanozymes in reactive oxygen species\u2010dependent diseases: from design and preclinical studies to clinical translation prospects. Small Struct. 2025. https:\/\/doi.org\/10.1002\/sstr.202500195.","journal-title":"Small Struct"},{"issue":"8","key":"4763_CR177","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/bios15080480","volume":"15","author":"F Gao","year":"2025","unstructured":"Gao F, Hou Y, Wang Y, Liu L, Yi X, Xia N. Photothermal and photodynamic strategies for diagnosis and therapy of Alzheimer\u2019s disease by modulating amyloid-\u03b2 aggregation. Biosensors. 2025;15(8):480.","journal-title":"Biosensors"},{"key":"4763_CR178","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X370790250317045223","author":"B \u00d6zt\u00fcrk","year":"2025","unstructured":"\u00d6zt\u00fcrk B, Demir H, G\u00fcnay MS, Akdag Y, Sahin S, Gulsun T. Photodynamic and photothermal therapies using nanotechnology approach in Alzheimer\u2019s disease. Curr Neuropharmacol. 2025. https:\/\/doi.org\/10.2174\/011570159X370790250317045223.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"4763_CR179","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/pharmaceutics15030916","volume":"15","author":"LM Ailioaie","year":"2023","unstructured":"Ailioaie LM, Ailioaie C, Litscher G. Photobiomodulation in Alzheimer\u2019s disease: a complementary method to state-of-the-art pharmaceutical formulations and nanomedicine? Pharmaceutics. 2023;15(3):916.","journal-title":"Pharmaceutics"},{"issue":"5","key":"4763_CR180","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/1567205016666190321163438","volume":"16","author":"L Pinheiro","year":"2019","unstructured":"Pinheiro L, Faustino C. Therapeutic strategies targeting amyloid-\u03b2 in Alzheimer\u2019s disease. Curr Alzheimer Res. 2019;16(5):418\u201352.","journal-title":"Curr Alzheimer Res"},{"key":"4763_CR181","doi-asserted-by":"crossref","unstructured":"Dey S, Hassan S, Pandey RK. Nanomedicine in targeted drug delivery: precision therapeutics for personalized medicine. Nanomedicine: Innovations, Applications, and Breakthroughs in the Quest for Health and Medicine\u2019s Future: Springer; 2024. p. 179\u2013231.","DOI":"10.1007\/978-3-031-72467-1_8"},{"issue":"11","key":"4763_CR182","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3390\/antiox11112167","volume":"11","author":"MC Jurc\u0103u","year":"2022","unstructured":"Jurc\u0103u MC, Andronie-Cioara FL, Jurc\u0103u A, Marcu F, \u0162i\u021b DM, Pa\u0219cal\u0103u N, et al. The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer\u2019s disease: therapeutic implications and future perspectives. Antioxidants. 2022;11(11):2167.","journal-title":"Antioxidants"},{"key":"4763_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.169081","author":"L Fu","year":"2025","unstructured":"Fu L, Huang Y, Sun X, Wang X, Li S, Wang X, et al. Reactive oxygen species activatable nanotherapeutics for evaluating and relieving nanoplastics-induced oxidative stress. Chem Eng J. 2025. https:\/\/doi.org\/10.1016\/j.cej.2025.169081.","journal-title":"Chem Eng J"},{"key":"4763_CR184","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-04782-z","author":"PR Dubey","year":"2025","unstructured":"Dubey PR, Kaur G, Shukla R. Nano-mediated management of metal toxicity-induced neurodegeneration: a critical review. Mol Neurobiol. 2025. https:\/\/doi.org\/10.1007\/s12035-025-04782-z.","journal-title":"Mol Neurobiol"},{"issue":"23","key":"4763_CR185","doi-asserted-by":"publisher","first-page":"2206575","DOI":"10.1002\/smll.202206575","volume":"19","author":"H Niu","year":"2023","unstructured":"Niu H, Bu H, Zhao J, Zhu Y. Metal\u2013organic frameworks-based nanoplatforms for the theranostic applications of neurological diseases. Small. 2023;19(23):2206575.","journal-title":"Small"},{"key":"4763_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2024.112601","volume":"257","author":"T Mazur","year":"2024","unstructured":"Mazur T, Malik M, Bie\u0144ko DC. The impact of chelating compounds on Cu2+, Fe2+\/3+, and Zn2+ ions in Alzheimer\u2019s disease treatment. J Inorg Biochem. 2024;257:112601.","journal-title":"J Inorg Biochem"},{"key":"4763_CR187","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251374149","author":"G Liu","year":"2025","unstructured":"Liu G, Sun Y. Harnessing nanoparticles for Alzheimer\u2019s disease: innovations in drug delivery and pathology-specific treatments. J Alzheimers Dis. 2025. https:\/\/doi.org\/10.1177\/13872877251374149.","journal-title":"J Alzheimers Dis"},{"key":"4763_CR188","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2015.12.013","volume":"240","author":"F Zhang","year":"2016","unstructured":"Zhang F, Lin YA, Kannan S, Kannan RM. Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release. 2016;240:212\u201326.","journal-title":"J Control Release"},{"key":"4763_CR189","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jconrel.2020.01.039","volume":"320","author":"Q Guo","year":"2020","unstructured":"Guo Q, Xu S, Yang P, Wang P, Lu S, Sheng D, et al. A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer\u2019s disease mice. J Control Release. 2020;320:347\u201362.","journal-title":"J Control Release"},{"issue":"3","key":"4763_CR190","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neulet.2009.03.064","volume":"455","author":"G Liu","year":"2009","unstructured":"Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett. 2009;455(3):187\u201390.","journal-title":"Neurosci Lett"},{"issue":"39","key":"4763_CR191","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202203031","volume":"18","author":"C Du","year":"2022","unstructured":"Du C, Feng W, Dai X, Wang J, Geng D, Li X, et al. Cu(2+) -Chelatable and ROS-scavenging MXenzyme as NIR-II-triggered blood-brain barrier-crossing nanocatalyst against Alzheimer\u2019s disease. Small. 2022;18(39):e2203031.","journal-title":"Small"},{"key":"4763_CR192","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201703458","author":"W Chen","year":"2018","unstructured":"Chen W, Ouyang J, Yi X, Xu Y, Niu C, Zhang W, et al. Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv Mater. 2018. https:\/\/doi.org\/10.1002\/adma.201703458.","journal-title":"Adv Mater"},{"issue":"1","key":"4763_CR193","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1038\/s41598-017-03411-7","volume":"7","author":"P Boonruamkaew","year":"2017","unstructured":"Boonruamkaew P, Chonpathompikunlert P, Vong LB, Sakaue S, Tomidokoro Y, Ishii K, et al. Chronic treatment with a smart antioxidative nanoparticle for inhibition of amyloid plaque propagation in Tg2576 mouse model of Alzheimer\u2019s disease. Sci Rep. 2017;7(1):3785.","journal-title":"Sci Rep"},{"issue":"1","key":"4763_CR194","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1038\/s41467-020-16544-7","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Xiao B, Xiang F, Tan J, Chen Z, Zhang X, et al. Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases. Nat Commun. 2020;11(1):2788.","journal-title":"Nat Commun"},{"key":"4763_CR195","doi-asserted-by":"publisher","unstructured":"Chacko L, Nag S, Dewanjee S, Ghosh S, Vallamkondu J, Mitra O, Dey A, Bhuniya T, Paluru HP, Reddy PH, Kandimalla R. Nano-theranostics approaches and mitochondrial targeted drug delivery: Alzheimer's disease therapeutic interventions. Preprints. 2022 Nov 1. https:\/\/doi.org\/10.20944\/preprints202211.0032.v1","DOI":"10.20944\/preprints202211.0032.v1"},{"key":"4763_CR196","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202502178","author":"YF Zhu","year":"2025","unstructured":"Zhu YF, He MQ, Lin CS, Ma WH, Ai Y, Wang J, et al. Multifunctional nanocarrier drug delivery systems: from diverse design to precise biomedical applications. Adv Healthc Mater. 2025. https:\/\/doi.org\/10.1002\/adhm.202502178.","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"4763_CR197","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/biom15091316","volume":"15","author":"M Olaz\u00e1bal-Mor\u00e1n","year":"2025","unstructured":"Olaz\u00e1bal-Mor\u00e1n M, P\u00e9rez E, Esteban-Arranz A, Garrido A. The role of reactive oxygen species in lung cancer development: nanomedicine as a therapeutic strategy. Biomolecules. 2025;15(9):1316.","journal-title":"Biomolecules"},{"issue":"2","key":"4763_CR198","first-page":"55","volume":"1","author":"L Wang","year":"2024","unstructured":"Wang L, Chen F, Zhang C, Cheng YY, Bu W, Liu Y. Reactive oxygen species and neurodegenerative diseases: insights into nanozyme therapeutics. Med Mat. 2024;1(2):55\u201373.","journal-title":"Med Mat"},{"issue":"13\u201315","key":"4763_CR199","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1089\/ars.2022.0107","volume":"40","author":"I Hasan","year":"2024","unstructured":"Hasan I, Guo B, Zhang J, Chang C. Advances in antioxidant nanomedicines for imaging and therapy of Alzheimer\u2019s disease. Antioxid Redox Signal. 2024;40(13\u201315):863\u201388.","journal-title":"Antioxid Redox Signal"},{"key":"4763_CR200","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202515330","author":"L Zhou","year":"2025","unstructured":"Zhou L, Guo J, Yang H, Yuan Y, Fan J, Chen X, et al. Extracellular vesicle\u2013based biohybrid enabling synergistic anti\u2010oxidative stress and anti\u2010inflammation for targeted therapy of acute kidney injury. Adv Funct Mater. 2025. https:\/\/doi.org\/10.1002\/adfm.202515330.","journal-title":"Adv Funct Mater"},{"key":"4763_CR201","doi-asserted-by":"publisher","unstructured":"Adilovi\u0107 M, Uversky VN, \u0160utkovi\u0107 J. Macromolecular crowding in cytoplasm and cellular organelles. In: Uversky VN, editor. (Macro)Molecular Crowding: Life of the Pottage. Subcellular Biochemistry. Vol. 109. Cham (Switzerland): Springer Nature Switzerland; 2025. p. 209\u2013240. https:\/\/doi.org\/10.1007\/978-3-032-03370-3_10","DOI":"10.1007\/978-3-032-03370-3_10"},{"key":"4763_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124397","volume":"661","author":"H Huang","year":"2024","unstructured":"Huang H, Yang L, He H, Zhou B, Qin Z, Zheng L, et al. Construction of mitochondrial-targeting nano-prodrug for enhanced Rhein delivery and treatment for osteoarthritis in vitro. Int J Pharm. 2024;661:124397.","journal-title":"Int J Pharm"},{"issue":"6","key":"4763_CR203","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/medicina61060981","volume":"61","author":"A-M Trofin","year":"2025","unstructured":"Trofin A-M, Scripcariu DV, Filipiuc S-I, Neagu A-N, Filipiuc L-E, Tamba B-I, et al. From nature to nanomedicine: enhancing the antitumor efficacy of Rhein, Curcumin, and Resveratrol. Medicina. 2025;61(6):981.","journal-title":"Medicina"},{"issue":"6","key":"4763_CR204","first-page":"368","volume":"14","author":"AK Dutta","year":"2025","unstructured":"Dutta AK, Srinivasulu C, Sunanda M, Lakshmi PV, Baratha N. Stem cell therapy in regenerative medicine current progress, challenges, and future prospects. J Neonatal Surg. 2025;14(6):368.","journal-title":"J Neonatal Surg"},{"key":"4763_CR205","doi-asserted-by":"publisher","DOI":"10.20517\/evcna.2025.65","author":"M Kumar","year":"2025","unstructured":"Kumar M, Ray S, Sil S. Stem-cell-derived extracellular vesicles in neurodegeneration and neuroaging: therapeutic potential and challenges. Extracell Vesicles Circulat Nucleic Acids. 2025. https:\/\/doi.org\/10.20517\/evcna.2025.65.","journal-title":"Extracell Vesicles Circulat Nucleic Acids"},{"issue":"12","key":"4763_CR206","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1097\/JS9.0000000000002111","volume":"110","author":"D Banerjee","year":"2024","unstructured":"Banerjee D, Bhattacharya A, Puri A, Munde S, Mukerjee N, Mohite P, et al. Innovative approaches in stem cell therapy: revolutionizing cancer treatment and advancing neurobiology\u2013a comprehensive review. Int J Surg. 2024;110(12):7528\u201345.","journal-title":"Int J Surg"},{"issue":"19","key":"4763_CR207","doi-asserted-by":"publisher","first-page":"9528","DOI":"10.3390\/ijms26199528","volume":"26","author":"L Ruccolo","year":"2025","unstructured":"Ruccolo L, Evangelista A, Benazzo M, Conti B, Pisani S. Electrospun bio-scaffolds for mesenchymal stem cell-mediated neural differentiation: systematic review of advances and future directions. Int J Mol Sci. 2025;26(19):9528.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4763_CR208","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/biomedicines12020403","volume":"12","author":"S Saha","year":"2024","unstructured":"Saha S, Sachivkina N, Karamyan A, Novikova E, Chubenko T. Advances in Nrf2 signaling pathway by targeted nanostructured-based drug delivery systems. Biomedicines. 2024;12(2):403.","journal-title":"Biomedicines"},{"issue":"4","key":"4763_CR209","volume":"19","author":"K Qian","year":"2024","unstructured":"Qian K, Yang P, Li Y, Meng R, Cheng Y, Zhou L, et al. Rational fusion design inspired by cell-penetrating peptide: SS31\/S-14 G Humanin hybrid peptide with amplified multimodal efficacy and bio-permeability for the treatment of Alzheimer\u2019s disease. Asian J Pharm Sci. 2024;19(4):100938.","journal-title":"Asian J Pharm Sci"},{"issue":"7","key":"4763_CR210","doi-asserted-by":"publisher","first-page":"11455","DOI":"10.1021\/acsnano.2c05795","volume":"16","author":"K Qian","year":"2022","unstructured":"Qian K, Bao X, Li Y, Wang P, Guo Q, Yang P, et al. Cholinergic neuron targeting nanosystem delivering hybrid peptide for combinatorial mitochondrial therapy in Alzheimer\u2019s disease. ACS Nano. 2022;16(7):11455\u201372.","journal-title":"ACS Nano"},{"issue":"26","key":"4763_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202100746","volume":"33","author":"P Liu","year":"2021","unstructured":"Liu P, Zhang T, Chen Q, Li C, Chu Y, Guo Q, et al. biomimetic dendrimer-peptide conjugates for early multi-target therapy of Alzheimer\u2019s disease by inflammatory microenvironment modulation. Adv Mater. 2021;33(26):e2100746.","journal-title":"Adv Mater"},{"issue":"2","key":"4763_CR212","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.freeradbiomed.2011.10.486","volume":"52","author":"R Hancock","year":"2012","unstructured":"Hancock R, Bertrand HC, Tsujita T, Naz S, El-Bakry A, Laoruchupong J, et al. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction. Free Radic Biol Med. 2012;52(2):444\u201351.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"4763_CR213","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1021\/acsami.2c18060","volume":"15","author":"Z Yin","year":"2023","unstructured":"Yin Z, Zhang Z, Gao D, Luo G, Ma T, Wang Y, et al. Stepwise coordination-driven metal-phenolic nanoparticle as a neuroprotection enhancer for Alzheimer\u2019s disease therapy. ACS Appl Mater Interfaces. 2023;15(1):524\u201340.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"4763_CR214","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/hmg\/ddx052","volume":"26","author":"PH Reddy","year":"2017","unstructured":"Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer\u2019s disease. Hum Mol Genet. 2017;26(8):1483\u201396.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"4763_CR215","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3233\/JAD-170988","volume":"62","author":"PH Reddy","year":"2018","unstructured":"Reddy PH, Manczak M, Yin X, Reddy AP. Synergistic protective effects of mitochondrial division inhibitor 1 and mitochondria-targeted small peptide SS31 in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;62(4):1549\u201365.","journal-title":"J Alzheimers Dis"},{"key":"4763_CR216","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050488","author":"PH Reddy","year":"2019","unstructured":"Reddy PH, Oliver DM. Amyloid beta and phosphorylated Tau-induced Defective autophagy and mitophagy in Alzheimer\u2019s disease. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8050488.","journal-title":"Cells"},{"issue":"49","key":"4763_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207107","volume":"34","author":"F Xu","year":"2022","unstructured":"Xu F, Wu Y, Yang Q, Cheng Y, Xu J, Zhang Y, et al. Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer\u2019s disease Treatment. Adv Mater. 2022;34(49):e2207107.","journal-title":"Adv Mater"},{"issue":"36","key":"4763_CR218","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.2174\/0929867328666210406115529","volume":"28","author":"I Cs\u00f3ka","year":"2021","unstructured":"Cs\u00f3ka I, Ismail R, J\u00f3j\u00e1rt-Laczkovich O, Pallagi E. Regulatory considerations, challenges and risk-based approach in nanomedicine development. Curr Med Chem. 2021;28(36):7461\u201376.","journal-title":"Curr Med Chem"},{"issue":"5","key":"4763_CR219","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.drudis.2018.01.047","volume":"23","author":"V Agrahari","year":"2018","unstructured":"Agrahari V, Agrahari V. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discov Today. 2018;23(5):974\u201391.","journal-title":"Drug Discov Today"},{"issue":"1","key":"4763_CR220","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12974-025-03360-3","volume":"22","author":"C Acioglu","year":"2025","unstructured":"Acioglu C, Elkabes S. Innate immune sensors and regulators at the blood brain barrier: focus on toll-like receptors and inflammasomes as mediators of neuro-immune crosstalk and inflammation. J Neuroinflammation. 2025;22(1):39.","journal-title":"J Neuroinflammation"},{"key":"4763_CR221","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S483412","author":"S Zhang","year":"2024","unstructured":"Zhang S, Gao Z, Feng L, Li M. Prevention and treatment strategies for Alzheimer\u2019s disease: focusing on microglia and astrocytes in neuroinflammation. J Inflamm Res. 2024. https:\/\/doi.org\/10.2147\/JIR.S483412.","journal-title":"J Inflamm Res"},{"key":"4763_CR222","doi-asserted-by":"publisher","first-page":"1347987","DOI":"10.3389\/fnagi.2024.1347987","volume":"16","author":"A Adamu","year":"2024","unstructured":"Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024;16:1347987.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"4763_CR223","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12974-025-03443-1","volume":"22","author":"J Han","year":"2025","unstructured":"Han J, Zhang X, Kang L, Guan J. Extracellular vesicles as therapeutic modulators of neuroinflammation in Alzheimer\u2019s disease: a focus on signaling mechanisms. J Neuroinflammation. 2025;22(1):120.","journal-title":"J Neuroinflammation"},{"key":"4763_CR224","doi-asserted-by":"publisher","DOI":"10.18502\/igj.v8i2.17998","author":"M Rafiyan","year":"2025","unstructured":"Rafiyan M, Mojtahedi H, Rezaei N. Role of neuroinflammation in Alzheimer\u2019s disease (AD). Immunol Gene J. 2025. https:\/\/doi.org\/10.18502\/igj.v8i2.17998.","journal-title":"Immunol Gene J"},{"issue":"1","key":"4763_CR225","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/0115748855342971240816120237","volume":"20","author":"J He","year":"2025","unstructured":"He J, Zeng W, Ye X, Niu X, Liu J, Chen Z. Targeted drug delivery for precision mitochondrial therapy in osteoporosis: therapeutic strategies and advances. Current Drug Therapy. 2025;20(1):76\u201394.","journal-title":"Current Drug Therapy"},{"key":"4763_CR226","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.845185","volume":"13","author":"T Liang","year":"2022","unstructured":"Liang T, Zhang Y, Wu S, Chen Q, Wang L. The role of NLRP3 inflammasome in Alzheimer\u2019s disease and potential therapeutic targets. Front Pharmacol. 2022;13:845185.","journal-title":"Front Pharmacol"},{"key":"4763_CR227","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-04818-4","author":"HM Saad","year":"2025","unstructured":"Saad HM, Atef E, Elsayed AE. New insights on the potential role of pyroptosis in Parkinson\u2019s neuropathology and therapeutic targeting of NLRP3 inflammasome with recent advances in nanoparticle-based miRNA therapeutics. Mol Neurobiol. 2025. https:\/\/doi.org\/10.1007\/s12035-025-04818-4.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"4763_CR228","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.3390\/ijms24098151","volume":"24","author":"M Govindarajulu","year":"2023","unstructured":"Govindarajulu M, Ramesh S, Beasley M, Lynn G, Wallace C, Labeau S, et al. Role of cGAS\u2013sting signaling in Alzheimer\u2019s disease. Int J Mol Sci. 2023;24(9):8151.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4763_CR229","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/ijms24021226","volume":"24","author":"L \u00c1lvarez-S\u00e1nchez","year":"2023","unstructured":"\u00c1lvarez-S\u00e1nchez L, Pe\u00f1a-Bautista C, Ferr\u00e9-Gonz\u00e1lez L, Balaguer A, Baquero M, Casanova-Estruch B, et al. Assessment of plasma and cerebrospinal fluid biomarkers in different stages of Alzheimer\u2019s disease and frontotemporal dementia. Int J Mol Sci. 2023;24(2):1226.","journal-title":"Int J Mol Sci"},{"key":"4763_CR230","unstructured":"Ijaz S, Iqbal J, Abbasi BA, Yaseen T, Ashraf Z, Iqbal R, et al. Biomedical application of green nanoparticles: insights into the anti-inflammatory molecular mechanisms. In: Khalil AT, Islam A, editors. Expanding Nanobiotechnology: Applications and Commercialization. Boca Raton (FL): CRC Press; 2025. p. 182\u2013211."},{"issue":"5","key":"4763_CR231","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/pharmaceutics17050661","volume":"17","author":"M Gomes","year":"2025","unstructured":"Gomes M, Ramalho MJ, Loureiro JA, Pereira MC. Advancing brain targeting: cost-effective surface-modified nanoparticles for faster market entry. Pharmaceutics. 2025;17(5):661.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4763_CR232","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12974-023-02751-8","volume":"20","author":"M Kapoor","year":"2023","unstructured":"Kapoor M, Chinnathambi S. TGF-\u03b21 signalling in Alzheimer\u2019s pathology and cytoskeletal reorganization: a specialized Tau perspective. J Neuroinflammation. 2023;20(1):72.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"4763_CR233","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.70025","volume":"17","author":"V Sundaram","year":"2025","unstructured":"Sundaram V, Aryal S. Emerging biomimetic drug delivery nanoparticles inspired by extracellular vesicles. Wiley Interdisciplin Rev Nanomed Nanobiotechnol. 2025;17(4):e70025.","journal-title":"Wiley Interdisciplin Rev Nanomed Nanobiotechnol"},{"issue":"2","key":"4763_CR234","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/ma16020699","volume":"16","author":"H Ashraf","year":"2023","unstructured":"Ashraf H, Cossu D, Ruberto S, Noli M, Jasemi S, Simula ER, et al. Latent potential of multifunctional selenium nanoparticles in neurological diseases and altered gut microbiota. Materials. 2023;16(2):699.","journal-title":"Materials"},{"issue":"2","key":"4763_CR235","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41380-022-01841-y","volume":"28","author":"H Yao","year":"2023","unstructured":"Yao H, Zhang D, Yu H, Yuan H, Shen H, Lan X, et al. Gut microbiota regulates chronic ethanol exposure-induced depressive-like behavior through hippocampal NLRP3-mediated neuroinflammation. Mol Psychiatry. 2023;28(2):919\u201330.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"4763_CR236","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-023-00393-7","volume":"13","author":"HM Gebril","year":"2024","unstructured":"Gebril HM, Aryasomayajula A, de Lima MRN, Uhrich KE, Moghe PV. Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer\u2019s pathology. Transl Neurodegener. 2024;13(1):2.","journal-title":"Transl Neurodegener"},{"issue":"19","key":"4763_CR237","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400125","volume":"13","author":"HC Wang","year":"2024","unstructured":"Wang HC, Yang W, Xu L, Han YH, Lin Y, Lu CT, et al. BV2 membrane-coated PEGylated-liposomes delivered hFGF21 to cortical and hippocampal microglia for Alzheimer\u2019s disease therapy. Adv Healthc Mater. 2024;13(19):e2400125.","journal-title":"Adv Healthc Mater"},{"key":"4763_CR238","first-page":"337","volume":"26","author":"M Cheng","year":"2023","unstructured":"Cheng M, Ye C, Tian C, Zhao D, Li H, Sun Z, et al. Engineered macrophage-biomimetic versatile nanoantidotes for inflammation-targeted therapy against Alzheimer\u2019s disease by neurotoxin neutralization and immune recognition suppression. Bioact Mater. 2023;26:337\u201352.","journal-title":"Bioact Mater"},{"issue":"37","key":"4763_CR239","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1039\/D1TB01290H","volume":"9","author":"X Yuan","year":"2021","unstructured":"Yuan X, Jia Z, Li J, Liu Y, Huang Y, Gong Y, et al. A diselenide bond-containing ROS-responsive ruthenium nanoplatform delivers nerve growth factor for Alzheimer\u2019s disease management by repairing and promoting neuron regeneration. J Mater Chem B. 2021;9(37):7835\u201347.","journal-title":"J Mater Chem B"},{"key":"4763_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2026.103055","volume":"38","author":"Y Yu","year":"2026","unstructured":"Yu Y, Yu JJ, Ding SW, Zhang G, Liu Y, Guo RB, et al. An engineered ROS-responsive cascade nanoplatform delays Alzheimer\u2019s disease progression via Nrf2\/GPX4-mediated microglial functional reprogramming. Mater Today Bio. 2026;38:103055.","journal-title":"Mater Today Bio"},{"issue":"4","key":"4763_CR241","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41419-022-04765-1","volume":"13","author":"W Yi-Bin","year":"2022","unstructured":"Yi-Bin W, Xiang L, Bing Y, Qi Z, Fei-Tong J, Minghong W, et al. Inhibition of the CEBP\u03b2-NF\u03baB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer\u2019s disease model. Cell Death Dis. 2022;13(4):318.","journal-title":"Cell Death Dis"},{"issue":"12","key":"4763_CR242","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300180","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen H, Zhang W, Liu Y, Ding L, Gong J, et al. Biomimetic remodeling of microglial Riboflavin metabolism ameliorates cognitive impairment by modulating neuroinflammation. Adv Sci (Weinh). 2023;10(12):e2300180.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"4763_CR243","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1007\/s12035-025-04758-z","volume":"62","author":"G Ayyubova","year":"2025","unstructured":"Ayyubova G, Madhu LN. Microglial NLRP3 inflammasomes in Alzheimer\u2019s disease pathogenesis: from interaction with autophagy\/mitophagy to therapeutics. Mol Neurobiol. 2025;62(6):7124\u201343.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"4763_CR244","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12035-013-8475-x","volume":"48","author":"MS Tan","year":"2013","unstructured":"Tan MS, Yu JT, Jiang T, Zhu XC, Tan L. The NLRP3 inflammasome in Alzheimer\u2019s disease. Mol Neurobiol. 2013;48(3):875\u201382.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"4763_CR245","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/jdn.10352","volume":"84","author":"X Qin","year":"2024","unstructured":"Qin X, Li B, Hu B, Huang J, Tian X, Zhang X, et al. Rhein inhibits M1 polarization of BV2 microglia through MAPK\/I\u03baB signalling pathway and reduces neurotoxicity caused by neuroinflammation. Int J Dev Neurosci. 2024;84(6):533\u201345.","journal-title":"Int J Dev Neurosci"},{"issue":"19","key":"4763_CR246","doi-asserted-by":"publisher","first-page":"21822","DOI":"10.1021\/acsami.2c00007","volume":"14","author":"C Ye","year":"2022","unstructured":"Ye C, Cheng M, Ma L, Zhang T, Sun Z, Yu C, et al. Oxytocin nanogels inhibit innate Inflammatory response for early intervention in Alzheimer\u2019s disease. ACS Appl Mater Interfaces. 2022;14(19):21822\u201335.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4763_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.149393","volume":"1850","author":"RAL De Sousa","year":"2025","unstructured":"De Sousa RAL, Mendes BF. T-regulatory cells and extracellular vesicles in Alzheimer\u2019s disease: new therapeutic concepts and hypotheses. Brain Res. 2025;1850:149393.","journal-title":"Brain Res"},{"issue":"6","key":"4763_CR248","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1021\/acs.molpharmaceut.4c00233","volume":"21","author":"T Wu","year":"2024","unstructured":"Wu T, Wang L, Gao C, Jian C, Liu Y, Fu Z, et al. Treg-derived extracellular vesicles: roles in diseases and theranostics. Mol Pharm. 2024;21(6):2659\u201372.","journal-title":"Mol Pharm"},{"issue":"4","key":"4763_CR249","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s11481-023-10090-x","volume":"18","author":"L Yuan","year":"2023","unstructured":"Yuan L, Xie L, Zhang H, Zhang Y, Wei Y, Feng J, et al. Low-dose IL-2 treatment rescues cognitive deficits by repairing the imbalance between Treg and Th17 cells at the middle Alzheimer\u2019s disease stage. J Neuroimmune Pharmacol. 2023;18(4):674\u201389.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"4763_CR250","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s40478-022-01447-z","volume":"10","author":"A Faridar","year":"2022","unstructured":"Faridar A, Vasquez M, Thome AD, Yin Z, Xuan H, Wang JH, et al. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2022;10(1):144.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4763_CR251","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13024-023-00692-7","volume":"18","author":"P Yeapuri","year":"2023","unstructured":"Yeapuri P, Machhi J, Lu Y, Abdelmoaty MM, Kadry R, Patel M, et al. Amyloid-\u03b2 specific regulatory T cells attenuate Alzheimer\u2019s disease pathobiology in APP\/PS1 mice. Mol Neurodegener. 2023;18(1):97.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"4763_CR252","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207719","volume":"35","author":"M Jung","year":"2023","unstructured":"Jung M, Lee S, Park S, Hong J, Kim C, Cho I, et al. A Therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for Alzheimer\u2019s disease. Adv Mater. 2023;35(3):e2207719.","journal-title":"Adv Mater"},{"key":"4763_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109884","volume":"100","author":"H Shen","year":"2020","unstructured":"Shen H, Guan Q, Zhang X, Yuan C, Tan Z, Zhai L, et al. New mechanism of neuroinflammation in Alzheimer\u2019s disease: The activation of NLRP3 inflammasome mediated by gut microbiota. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109884.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"27","key":"4763_CR254","doi-asserted-by":"publisher","first-page":"30557","DOI":"10.1021\/acsami.2c06283","volume":"14","author":"L Yang","year":"2022","unstructured":"Yang L, Cui Y, Liang H, Li Z, Wang N, Wang Y, et al. Multifunctional selenium nanoparticles with different surface modifications ameliorate neuroinflammation through the gut microbiota-NLRP3 inflammasome-brain axis in APP\/PS1 mice. ACS Appl Mater Interfaces. 2022;14(27):30557\u201370.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4763_CR255","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12974-019-1453-0","volume":"16","author":"DA Dionisio-Santos","year":"2019","unstructured":"Dionisio-Santos DA, Olschowka JA, O\u2019Banion MK. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer\u2019s disease. J Neuroinflammation. 2019;16(1):74.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"4763_CR256","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13024-025-00812-5","volume":"20","author":"S Zhang","year":"2025","unstructured":"Zhang S, Gao Y, Zhao Y, Huang TY, Zheng Q, Wang X. Peripheral and central neuroimmune mechanisms in Alzheimer\u2019s disease pathogenesis. Mol Neurodegener. 2025;20(1):22.","journal-title":"Mol Neurodegener"},{"key":"4763_CR257","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.2147\/IJN.S436774","volume":"18","author":"C Gao","year":"2023","unstructured":"Gao C, Liu Y, Zhang TL, Luo Y, Gao J, Chu JJ, et al. Biomembrane-derived nanoparticles in Alzheimer\u2019s disease therapy: a comprehensive review of synthetic lipid nanoparticles and natural cell-derived vesicles. Int J Nanomedicine. 2023;18:7441\u201368.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"4763_CR258","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s12015-025-10841-8","volume":"21","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yousefi M, Ghasemzadeh Fard MR, Masihpour N, Ali Khiavi P, Yousefi K, et al. Revitalizing vision: eye drops and corneal limbal stem cells survival. Stem Cell Rev Rep. 2025;21(3):730\u2013743. https:\/\/doi.org\/10.1007\/s12015-025-10841-8","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"4763_CR259","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/pharmaceutics17040456","volume":"17","author":"M Rasekh","year":"2025","unstructured":"Rasekh M, Arshad MS, Ahmad Z. Advances in drug delivery integrated with regenerative medicine: innovations, challenges, and future frontiers. Pharmaceutics. 2025;17(4):456.","journal-title":"Pharmaceutics"},{"key":"4763_CR260","doi-asserted-by":"publisher","first-page":"1763855","DOI":"10.3389\/fbioe.2026.1763855","volume":"14","author":"Y Guo","year":"2026","unstructured":"Guo Y, Dong X, Liu M, Liu D, Wang J. Integrating 3D bioprinting and neural stem cell therapy for central nervous system repair: implications for regenerative neurosurgery. Front Bioeng Biotechnol. 2026;14:1763855.","journal-title":"Front Bioeng Biotechnol"},{"issue":"17","key":"4763_CR261","doi-asserted-by":"publisher","first-page":"1705694","DOI":"10.1002\/adma.201705694","volume":"30","author":"B Zhang","year":"2018","unstructured":"Zhang B, Yan W, Zhu Y, Yang W, Le W, Chen B, et al. Nanomaterials in neural-stem-cell-mediated regenerative medicine: imaging and treatment of neurological diseases. Adv Mater. 2018;30(17):1705694.","journal-title":"Adv Mater"},{"issue":"52","key":"4763_CR262","doi-asserted-by":"publisher","first-page":"2410714","DOI":"10.1002\/adfm.202410714","volume":"34","author":"Y Wang","year":"2024","unstructured":"Wang Y, Sun C, Liu Z, Zhang S, Gao K, Yi F, et al. Nanoengineered endocytic biomaterials for stem cell therapy. Adv Func Mater. 2024;34(52):2410714.","journal-title":"Adv Func Mater"},{"key":"4763_CR263","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-025-01730-5","author":"TC Jangam","year":"2025","unstructured":"Jangam TC, Desai SA, Patel VP, Pagare NB, Raut ND. Exosomes as therapeutic and diagnostic tools: advances, challenges, and future directions. Cell Biochem Biophys. 2025. https:\/\/doi.org\/10.1007\/s12013-025-01730-5.","journal-title":"Cell Biochem Biophys"},{"issue":"1","key":"4763_CR264","doi-asserted-by":"publisher","first-page":"20250211","DOI":"10.1515\/ntrev-2025-0211","volume":"14","author":"R Ayub","year":"2025","unstructured":"Ayub R, Afzal M, Tabish M. Antioxidant quantum dots for spinal cord injuries: a review on advancing neuroprotection and regeneration in neurological disorders. Nanotechnol Rev. 2025;14(1):20250211.","journal-title":"Nanotechnol Rev"},{"issue":"9","key":"4763_CR265","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/medicina60091384","volume":"60","author":"A Krsek","year":"2024","unstructured":"Krsek A, Jagodic A, Baticic L. Nanomedicine in neuroprotection, neuroregeneration, and blood-Brain barrier modulation: a narrative review. Medicina. 2024;60(9):1384.","journal-title":"Medicina"},{"issue":"9","key":"4763_CR266","first-page":"100620074","volume":"10","author":"B Yu","year":"2021","unstructured":"Yu B, Shan Y, Ding J. A literature review of MRI techniques used to detect amyloid-beta plaques in Alzheimer\u2019s disease patients. Annal Palliat Med. 2021;10(9):100620074\u2013710074.","journal-title":"Annal Palliat Med"},{"key":"4763_CR267","doi-asserted-by":"publisher","DOI":"10.1007\/s12551-025-01358-y","author":"VV Zlobina","year":"2025","unstructured":"Zlobina VV, Mitkevich VA, Bershatsky YV, Volynsky PE, Pavlov KV, Karbyshev MS, et al. Transient cholesterol interactions with the amyloid precursor protein involved in Alzheimer\u2019s disease pathogenesis. Biophys Rev. 2025. https:\/\/doi.org\/10.1007\/s12551-025-01358-y.","journal-title":"Biophys Rev"},{"issue":"6","key":"4763_CR268","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1039\/D4RA08128E","volume":"15","author":"L Liu","year":"2025","unstructured":"Liu L, He H, Du B, He Y. Nanoscale drug formulations for the treatment of Alzheimer\u2019s disease progression. RSC Adv. 2025;15(6):4031\u201378.","journal-title":"RSC Adv"},{"issue":"13","key":"4763_CR269","doi-asserted-by":"publisher","first-page":"7673","DOI":"10.1039\/D4NR05298F","volume":"17","author":"N Mamidi","year":"2025","unstructured":"Mamidi N, De Silva FF, Mahmoudsalehi AO. Advanced disease therapeutics using engineered living drug delivery systems. Nanoscale. 2025;17(13):7673\u201396.","journal-title":"Nanoscale"}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04763-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:07:16Z","timestamp":1783094836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-026-04763-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":269,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4763"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04763-8","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}